-
South America, Asia, and Europe.
BioMarin's core
business and
research is in
enzyme replacement therapies (ERTs).
BioMarin was the
first company to provide...
-
typical cost of
treating a
patient with
Kuvan is US$100,000 per year.
BioMarin holds the
patent for
Kuvan until at
least 2024, but Par Pharmaceutical...
- gene
therapy used for the
treatment of
hemophilia A. It was
developed by
BioMarin Pharmaceutical.
Valoctocogene roxaparvovec is made of a
virus (AAV5) that...
- is a
synthetic version of this enzyme.
Elosulfase alfa was
developed by
BioMarin Pharmaceutical Inc. and
approved for use in the US by the Food and Drug...
-
Approves BioMarin's Voxzogo (vosoritide) for the
Treatment of
Children with
Achondroplasia from Age 2
Until Growth Plates Close" (Press release).
BioMarin Pharmaceutical...
-
Joseph (24
November 2014). "
BioMarin to Pay up to $840
Million for Prosensa". Wall
Street Journal. FDA
rejects BioMarin's muscle wasting drug; Sarepta...
-
mandated to
follow GMP, and they, as well as
BioMarin, are
subject to
inspection and review.
BioMarin's facility has
received both FDA and
European Commission...
- salt form,
which was
developed through a
series of
companies ending with
BioMarin Pharmaceutical which obtained European approval in 2009
under the trade...
- 2020-08-05. "
BioMarin : Pipeline :
Pipeline Overview : BMN 165 for PKU". bmrn.com.
Archived from the
original on 2015-01-01. "
BioMarin Provides Updates...
-
produced by
BioMarin for use in Type I MPS. In May 2005, galsulfase[Naglazyme®], a
recombinant enzyme replacement therapy also
produced by
Biomarin was approved...
